NCT07389941Not yet recruitingPhase 4
Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation
Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation (SPICE-AF)
Source: ClinicalTrials.gov · Last updated 11 Feb 2026
Brief summary (registry, in English)
To evaluate whether pre-treatment with semaglutide is superior to standard care in improving freedom from atrial fibrillation (AF) at 12 months following catheter ablation in patients with obesity and symptomatic AF undergoing first-time ablation.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- First submitted
- 28 Jan 2026
- Start date
- Oct 2026
- Primary completion date
- Apr 2029
- Lead sponsor
- University of Luebeck
- Diseases
- Atrial fibrillation
- NCT number
- NCT07389941
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 240
- From Oct 2026 to the primary completion date, Apr 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of glucacon-like peptide-1 receptor agonists or dipeptidyl peptidase 4 inhibitors or use within the last 90 days prior to screening
- Current antiobesity medication use or use within the last 90 days prior to screening
- A self-reported change in body weight of \>5 kg within 30 days before screening
- Hospitalization for unstable angina, or transient ischemic attack \<30 days prior to screening
- Pulmonary embolism \<90 days before screening
- Myocardial infarction, or stroke \<90 days prior to screening
- Acute pancreatitis \<180 days before screening
Other illness
- History of bariatric surgery
- History of diabetes mellitus
- Uncontrolled thyroid disease: thyroid-stimulating hormone \>10.0 mIU/L or \<0.4 mIU/L at screening
- Active malignancy
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
- Chronic inflammatory conditions requiring immunosuppression and/or on glucocorticoids
Lab values
- Chronic kidney disease with creatinine clearance \<30 mL/min
Other
- History or presence of chronic pancreatitis
- Pregnancy, breast-feeding or planning pregnancy
Who the study is looking for
- Age 18-80 years
- Symptomatic paroxysmal or persistent AF eligible for first-time catheter ablation
- Body mass index ≥30 kg/m or body mass index ≥28 kg/m plus ≥1 weight-related comorbidity
- No prior treatment with glucacon-like peptide-1 receptor agonists
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.